Dr. John Faessel's  Instablog

Dr. John Faessel
Send Message
Dr. John L. Faessel is a seasoned and respected Wall Street professional with industry-wide recognition for expertise in market strategy and analysis. He is widely recognized for his insights in public companies. For over 20-years Dr. Faessel’s ON THE MARKET reports have been widely distributed... More
  • Update on (CIGX) Happenings 1 comment
    Oct 17, 2011 12:49 PM | about stocks: RCPI

    Dr. John L. Faessel                  


    Commentary and Insights                                                                 



    Star Scientific Inc. (CIGX) Nasdaq


    Update on (CIGX) Happenings


    A flurry of newsworthy items has built up relating to progress in the research on the Star Scientific product Anatabloc™ and its marketing efforts by InVentiv Health.


    For the first time, the team of scientists who’ve been central to the research on the anti-inflammatory compound are initiating a series of scientific meetings targeting large audiences of physicians and scientists. The announcement of these meetings was first published on the Anatabloc™ website http://anatabloc.com/ (Though at present it’s no longer on the site—presumably because all the seats are filled?)


    The meetings follow publication of the recently peer-reviewed abstract of a paper on Anatabloc™ in the European Journal of Pharmacology, titled “Anatabine lowers Alzheimer's Aβ production in vitro and in vivo.”


    Key is that the abstract was the first peer-reviewed evaluation by a leading scientific and medical journal. Numerous other peer reviews of research documenting the beneficial effects of Anatabloc™ are currently underway.


    The milestone of peer review now provides a credibility standard in the background of the recently announced meetings, and can only lend additional authority and trustworthiness to the upcoming presentations; “additional” in the sense that the presenting scientists mentioned below already have resumes that reek of reputation, integrity, and ethics.


    I understand that the meetings, each in a different part of the country, will feature presentations by Michael Mullan, M.D. PhD, Director of Roskamp Institute; Paul Ladenson, M.D.,* Director of Endocrinology & Metabolism at Johns Hopkins School of Medicine; and Patrizio Caturegli, MPH, M.D., Associate Professor of Pathology and Endocrinology also at John Hopkins. From what I hear a very large turnout is expected for each of the venues and seating is “oversubscribed.”


    Of Note: Johns Hopkins is ranked the number one (1) hospital for 20 consecutive years by U.S. News and World Report.


    Another upcoming presentation, under the prestigious Paul Starr Award Lecture banner, will be by Dr. Ladenson at the 81st Annual Meeting of the American Thyroid Association,** and is entitled “The Medical Treatment of Hyperthyroidism: Past, Present, and Future.” Dr. Ladenson’s presentation is scheduled for the 27th of October.


    You may remember that Dr. Ladenson presented research on the effect of RCP-006 in helping stop thyroiditis in humans at the Roskamp Institute meeting that I attended and reported on in June. At that meeting Dr. Ladenson stated in his remarks that, “aside from (RCP-006), there is no known compound that stops thyroiditis.”


    The American Thyroid Association annual meeting, held every fall, brings together over 1,000 physicians and investigators from around the world to share the newest clinical and basic science research into thyroid disease.


    It is my opinion that the various meetings will fire an immense interest in the healing arts community about the beneficial effects of Anatabloc™. Numerous studies have been completed or are underway, and there is a clear and building groundswell of interest from the physician community. Obviously, the above-mentioned and highly credible professionals would not be out in the community telling this story if their research results weren't impressive. There are also an astonishing number of people who have spoken highly, even raved about Anatabloc™ in anecdotal stories. Check this Facebook link to see some of the anecdotal testimonials: http://www.facebook.com/Anatabloc?sk=wall



    It’s only a matter of time before major media coverage will grasp the remarkable and compelling weight of this story and follow with coverage.


    The commercial “launch” of Anatabloc™ is being orchestrated by marketing giant InVentiv Health (a Thomas H Lee Partners subsidiary). InVentiv is a $2 billion marketing and distribution business with experts in every aspect of product development, launch and commercialization. It has marketing and sales capabilities in 40 countries around the globe. I’m sure that InVentiv did much due diligence before it decided to take the Anatabloc™ product to market. Their client list includes many of the largest, most successful pharmaceutical and biotech companies in the world, including Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Novartis (NVS), Merck (MRK), Pfizer (PFE), and Eli Lilly (LLY). Also consider that InVentiv counts Pfizer as a client and remember that Lipitor sales were $10.7 billion in 2010.


    Recently announced details regarding InVentiv’s new marketing efforts: international shipping of Anatabloc™ is now offered to Canada, the United Kingdom, Australia, New Zealand, Italy, Belgium, Israel, Singapore, Ireland, France, Switzerland, Netherlands, South Africa, Argentina, Spain, Norway and Japan. In addition, Anatabloc™ is now available at a growing list of CVS and Rite Aid locations in some states in the USA.


    Thomas Lee Partners has invested approximately $22 billion of equity capital in more than 100 businesses with an aggregate purchase price of more than $150 billion.


    Link to the European Journal of Pharmacology abstract:



    Link to the program at the 81st Annual Meeting of the American Thyroid Association: http://www.thyroid.org/ann_mtg/2010_81st/program.html


    To view the Roskamp Institute ‘inflammaging research’ revealing how (RCP-006) Anatabloc™ is more than four (4) times more effective than either Celebrex or Voltarol and three (3) times more effective that Lipitor in reducing inflammation in whole human blood, see the links below:






    * Dr. Ladenson is the John Eager Howard Professor of Endocrinology and Director of the Division of Endocrinology and Metabolism at Johns Hopkins University, where he is also Professor of Medicine, Pathology, Oncology, Radiology, and International Health. In 2007, Dr. Ladenson was also named a University Distinguished Professor. Dr. Ladenson has served as editor-in-chief of the Journal of Clinical Endocrinology and Metabolism and is past president of the American Thyroid Association. He is a past recipient of the American Thyroid Association's Paul Starr Award for career achievements in thyroid research. His research interests focus on thyroid cancer, thyroid hormone analogues, and health economic aspects of thyroid disease management. Dr. Ladenson was raised in Missouri and educated at Dartmouth College, Oxford University, and Harvard Medical School. He completed his training in Internal Medicine and Endocrinology and Metabolism at Massachusetts General Hospital.


    ** The American Thyroid Association is the leading organization focused on thyroid biology and the prevention and treatment of thyroid disorders through excellence and innovation in research, clinical care, education, and public health.


    Star has revealed that it is working with McColl Partners LLC “structuring a controlled auction for bidding by pharmaceutical companies for licensing and/or co-venturing relationships.”


    I'm an investor in Star Scientific shares and have bought shares the open market and have no other affiliation with the company other than as a shareholder.


    The Star Scientific website: http://www.starscientific.com/


    Stocks: RCPI
Back To Dr. John Faessel's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • xnxtxsx2
    , contributor
    Comments (19) | Send Message
    There are 3 meetings this month listed in the healthcare section of the Anatabloc site, First one tomorrow
    17 Oct 2011, 06:02 PM Reply Like
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.